One illustrative case is the use of NPRL2 gene-therapy, which demonstrated promising antitumor efficacy in reversing anti-PD-1 resistance in KRAS/STK11-mutant NSCLC using an NSG mouse model. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.